(株)レナサイエンスの貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証GRT | 医薬品 | 4889/ - | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2022/03/18 | 日証協 | 323,400株 | -3.41% | 41,400株 | -59.01% | 607,030株 | -4.53% | 36,300株 | +62.78% |
2022/03/11 | 日証協 | 334,800株 | +8.81% | 101,000株 | +83.3% | 635,830株 | -4.17% | 22,300株 | -76.4% |
2022/03/04 | 日証協 | 307,700株 | +1.25% | 55,100株 | +32.13% | 663,530株 | +13.36% | 94,500株 | +31.8% |
2022/02/25 | 日証協 | 303,900株 | +0.6% | 41,700株 | +13.32% | 585,330株 | -4.69% | 71,700株 | +193.84% |
2022/02/18 | 日証協 | 302,100株 | 0% | 36,800株 | +441.18% | 614,130株 | -8.11% | 24,401株 | +0.83% |
2022/02/10 | 日証協 | 302,100株 | -10.06% | 6,800株 | -60.47% | 668,329株 | -6.44% | 24,200株 | -76.82% |
2022/02/04 | 日証協 | 335,900株 | -12.48% | 17,200株 | -84.09% | 714,329株 | +0.66% | 104,401株 | +44.8% |
2022/01/28 | 日証協 | 383,800株 | -20.03% | 108,100株 | +398.16% | 709,628株 | -7.01% | 72,100株 | -3.99% |
2022/01/21 | 日証協 | 479,900株 | -29.96% | 21,700株 | -77.63% | 763,128株 | -10.33% | 75,100株 | -28.95% |
2022/01/14 | 日証協 | 685,200株 | -20.53% | 97,000株 | -14.76% | 851,030株 | -10.63% | 105,700株 | -24.66% |
2022/01/07 | 日証協 | 862,200株 | +2.96% | 113,800株 | -67.73% | 952,228株 | +3.79% | 140,302株 | +8.67% |
2021/12/30 | 日証協 | 837,400株 | 0% | 352,700株 | 0% | 917,418株 | 0% | 129,112株 | 0% |
2021/12/24 | 日証協 | 837,400株 | +7.26% | 352,700株 | +5.98% | 917,418株 | +4.79% | 129,112株 | -3.43% |
2021/12/17 | 日証協 | 780,700株 | -9.83% | 332,800株 | -14.09% | 875,518株 | -4.17% | 133,700株 | -37.87% |
2021/12/10 | 日証協 | 865,800株 | -8.57% | 387,400株 | +3.5% | 913,618株 | -10.62% | 215,200株 | -27.41% |
2021/12/03 | 日証協 | 947,000株 | +6.05% | 374,300株 | +13.42% | 1,022,214株 | +8.43% | 296,468株 | +19.83% |
2021/11/26 | 日証協 | 893,000株 | +28.73% | 330,000株 | -32.6% | 942,758株 | +13.09% | 247,406株 | -26.96% |
2021/11/19 | 日証協 | 693,700株 | +156.07% | 489,600株 | +37.88% | 833,622株 | +77.93% | 338,730株 | -14.68% |
2021/11/05 | 日証協 | 151,500株 | +7.45% | 105,700株 | -2.49% | 420,720株 | +31.06% | 148,200株 | -8.8% |
※株式分割は考慮していませんのでご注意ください。
Page Top